|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||232.71 - 232.71|
|52-week range||232.71 - 232.71|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||6.30|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.